Compare LAB & IGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LAB | IGD |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Trusts Except Educational Religious and Charitable |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.9M | 448.8M |
| IPO Year | 2011 | N/A |
| Metric | LAB | IGD |
|---|---|---|
| Price | $1.67 | $5.83 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.35 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 215.3K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.15% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $169,737,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 79.77 | N/A |
| 52 Week Low | $0.92 | $4.60 |
| 52 Week High | $2.25 | $5.26 |
| Indicator | LAB | IGD |
|---|---|---|
| Relative Strength Index (RSI) | 74.87 | 57.38 |
| Support Level | $1.46 | $5.75 |
| Resistance Level | $1.51 | $5.83 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 98.21 | 100.00 |
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.